{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:50:37Z","timestamp":1761094237774,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bbmt.2020.05.003","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T19:27:21Z","timestamp":1589657241000},"page":"e237-e238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia: What is the Best Strategy?"],"prefix":"10.1016","volume":"26","author":[{"given":"Selin","family":"Kucukyurt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugrul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Emre","family":"Eskazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.05.003_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.02.006","article-title":"The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era","author":"Schmidt","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.05.003_bib0002","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation","volume":"36","author":"Savani","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.05.003_bib0003","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clml.2013.09.010","article-title":"A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation","volume":"14","author":"Shanavas","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2020.05.003_bib0004","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3109\/10428194.2014.910868","article-title":"The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation: can tyrosine kinase inhibitors replace donor lymphocyte infusions?","volume":"56","author":"Zeidner","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.05.003_bib0005","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"European Group for Blood and Marrow Transplantation and the European Leukemia Net. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"15","author":"Gratwohl","year":"2009","journal-title":"Cancer."},{"key":"10.1016\/j.bbmt.2020.05.003_bib0006","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.05.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2016.04.017","article-title":"Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia?","volume":"16","author":"DeFilipp","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2020.05.003_bib0008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10428194.2018.1473573","article-title":"Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors","volume":"60","author":"Erbilgin","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.05.003_bib0009","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.3109\/10428194.2015.1026819","article-title":"Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?","volume":"56","author":"Eskazan","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.05.003_bib0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bmt.2009.177","article-title":"Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT","volume":"45","author":"Chalandon","year":"2010","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:03Z","timestamp":1761059583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120302901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1083879120302901"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.05.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia: What is the Best Strategy?","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}